138 related articles for article (PubMed ID: 17997257)
1. Activity of ceftobiprole compared with those of other agents against Staphylococcus aureus strains with different resistotypes by time-kill analysis.
Lin G; Appelbaum PC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):233-5. PubMed ID: 17997257
[TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic activity of ceftobiprole compared with vancomycin versus methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-intermediate Staphylococcus aureus (VISA) and vancomycin-resistant Staphylococcus aureus (VRSA) using an in vitro model.
Zhanel GG; Voth D; Nichol K; Karlowsky JA; Noreddin AM; Hoban DJ
J Antimicrob Chemother; 2009 Aug; 64(2):364-9. PubMed ID: 19454524
[TBL] [Abstract][Full Text] [Related]
3. Activity of telavancin compared to other agents against coagulase-negative staphylococci with different resistotypes by time kill.
Lin G; Pankuch GA; Appelbaum PC; Kosowska-Shick K
Diagn Microbiol Infect Dis; 2012 Jul; 73(3):287-9. PubMed ID: 22575272
[TBL] [Abstract][Full Text] [Related]
4. Antistaphylococcal activity of ceftobiprole, a new broad-spectrum cephalosporin.
Bogdanovich T; Ednie LM; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2005 Oct; 49(10):4210-9. PubMed ID: 16189100
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of ceftobiprole, linezolid, tigecycline, and 23 other antimicrobial agents against Staphylococcus aureus isolates in China.
Wang H; Liu Y; Sun H; Xu Y; Xie X; Chen M
Diagn Microbiol Infect Dis; 2008 Oct; 62(2):226-9. PubMed ID: 18653301
[TBL] [Abstract][Full Text] [Related]
6. In-vitro profile of a new beta-lactam, ceftobiprole, with activity against methicillin-resistant Staphylococcus aureus.
Jones ME
Clin Microbiol Infect; 2007 Jun; 13 Suppl 2():17-24. PubMed ID: 17488372
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activity of telavancin, vancomycin and linezolid against heterogeneously vancomycin-intermediate Staphylococcus aureus (hVISA).
Leonard SN; Szeto YG; Zolotarev M; Grigoryan IV
Int J Antimicrob Agents; 2011 Jun; 37(6):558-61. PubMed ID: 21497067
[TBL] [Abstract][Full Text] [Related]
8. Comparative activity of the new lipoglycopeptide telavancin in the presence and absence of serum against 50 glycopeptide non-susceptible staphylococci and three vancomycin-resistant Staphylococcus aureus.
Leuthner KD; Cheung CM; Rybak MJ
J Antimicrob Chemother; 2006 Aug; 58(2):338-43. PubMed ID: 16787952
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of novel anti-MRSA cephalosporins and comparator antimicrobial agents against staphylococci involved in prosthetic joint infections.
Isnard C; Dhalluin A; Malandain D; Bruey Q; Auzou M; Michon J; Giard JC; Guérin F; Cattoir V
J Glob Antimicrob Resist; 2018 Jun; 13():221-225. PubMed ID: 29421316
[TBL] [Abstract][Full Text] [Related]
10. Antipneumococcal activity of ceftobiprole, a novel broad-spectrum cephalosporin.
Kosowska K; Hoellman DB; Lin G; Clark C; Credito K; McGhee P; Dewasse B; Bozdogan B; Shapiro S; Appelbaum PC
Antimicrob Agents Chemother; 2005 May; 49(5):1932-42. PubMed ID: 15855516
[TBL] [Abstract][Full Text] [Related]
11. In vitro activity of ceftobiprole on 440 Staphylococcus aureus strains isolated from bronchopulmonary infections.
Hodille E; Delouere L; Bouveyron C; Meugnier H; Bes M; Tristan A; Laurent F; Vandenesch F; Lina G; Dumitrescu O
Med Mal Infect; 2017 Mar; 47(2):152-157. PubMed ID: 27856079
[TBL] [Abstract][Full Text] [Related]
12. Activity of quinupristin/dalfopristin against extracellular and intracellular Staphylococcus aureus with various resistance phenotypes.
Baudoux P; Lemaire S; Denis O; Tulkens PM; Van Bambeke F; Glupczynski Y
J Antimicrob Chemother; 2010 Jun; 65(6):1228-36. PubMed ID: 20378672
[TBL] [Abstract][Full Text] [Related]
13. In vitro activities of ceftobiprole, tigecycline, daptomycin, and 19 other antimicrobials against methicillin-resistant Staphylococcus aureus strains from a national survey of Belgian hospitals.
Denis O; Deplano A; Nonhoff C; Hallin M; De Ryck R; Vanhoof R; De Mendonça R; Struelens MJ
Antimicrob Agents Chemother; 2006 Aug; 50(8):2680-5. PubMed ID: 16870758
[TBL] [Abstract][Full Text] [Related]
14. Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin.
Smith K; Perez A; Ramage G; Gemmell CG; Lang S
Int J Antimicrob Agents; 2009 Apr; 33(4):374-8. PubMed ID: 19101124
[TBL] [Abstract][Full Text] [Related]
15. In vitro activities of a novel cephalosporin, CB-181963 (CAB-175), against methicillin-susceptible or -resistant Staphylococcus aureus and glycopeptide-intermediate susceptible staphylococci.
Huang V; Brown WJ; Rybak MJ
Antimicrob Agents Chemother; 2004 Jul; 48(7):2719-23. PubMed ID: 15215134
[TBL] [Abstract][Full Text] [Related]
16. Antistaphylococcal activity of CB-181963 (CAB-175), an experimental parenteral cephalosporin.
Hoellman DB; Pankuch GA; Appelbaum PC
Antimicrob Agents Chemother; 2004 Oct; 48(10):4037-9. PubMed ID: 15388474
[TBL] [Abstract][Full Text] [Related]
17. Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees.
Yun HC; Ellis MW; Jorgensen JH
Diagn Microbiol Infect Dis; 2007 Dec; 59(4):463-6. PubMed ID: 17911001
[TBL] [Abstract][Full Text] [Related]
18. Activities of ceftobiprole, linezolid, vancomycin, and daptomycin against community-associated and hospital-associated methicillin-resistant Staphylococcus aureus.
Leonard SN; Cheung CM; Rybak MJ
Antimicrob Agents Chemother; 2008 Aug; 52(8):2974-6. PubMed ID: 18519721
[TBL] [Abstract][Full Text] [Related]
19. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of ceftobiprole, daptomycin, linezolid, and vancomycin against methicillin-resistant staphylococci associated with endocarditis and bone and joint infection.
Rouse MS; Steckelberg JM; Patel R
Diagn Microbiol Infect Dis; 2007 Jul; 58(3):363-5. PubMed ID: 17449212
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
